| Literature DB >> 33651574 |
Alexandre Brind'Amour1, Jean-Pierre Gagné1, Jean-Charles Hogue1, Éric Poirier1.
Abstract
Background: Two members from an academic tertiary hospital went to the National Cancer Institute in Tokyo, Japan, to learn how to perform an adequate D2 lymphadenectomy and to then introduce this technique in the surgical care of patients undergoing surgery for gastric cancer at a Western hospital. We aimed to compare the perioperative outcomes and long-term survival of Western patients who underwent gastric resection, performed by these 2 surgeons, before and after the surgeons' shortcourse technical training in Japan.Entities:
Year: 2021 PMID: 33651574 PMCID: PMC8064251 DOI: 10.1503/cjs.019919
Source DB: PubMed Journal: Can J Surg ISSN: 0008-428X Impact factor: 2.089
Patient demographic and clinical characteristics
| Variable | No. (%) of patients | |||
|---|---|---|---|---|
| All | Pre-training | Post-training | ||
| Sex | 0.03 | |||
| Male | 74 (69.8) | 14 (51.8) | 60 (75.9) | |
| Female | 32 (30.2) | 13 (48.2) | 19 (24.1) | |
| Body mass index, mean ± SD, kg/m2 | 25.2 ± 5.3 | 23.9 ± 4.1 | 25.6 ± 5.6 | 0.17 |
| Age, mean ± SD, yr | 69.5 ± 12.2 | 69.9 ± 11.7 | 68.0 ± 12.4 | 0.51 |
| Comorbidities | 0.57 | |||
| Hypertension | 45 (42.5) | 12 (44.4) | 11 (13.9) | |
| Diabetes mellitus | 20 (18.9) | 3 (11.1) | 39 (49.4) | |
| Cardiovascular disease | 27 (25.5) | 9 (33.3) | 17 (21.5) | |
| Renal failure | 4 (3.8) | 1 (3.7) | 1 (1.3) | |
| Presentation | 0.41 | |||
| Obstructive lesion | 12 (11.3) | 1 (3.7) | 11 (13.9) | |
| Anemia | 52 (49.1) | 13 (48.2) | 39 (49.4) | |
| Abdominal pain | 23 (21.7) | 6 (22.2) | 17 (21.5) | |
| Weight loss | 46 (43.4) | 14 (51.9) | 32 (40.5) | |
| Other | 19 (17.9) | 4 (14.8) | 15 (19.0) | |
| Tumour location | 0.04 | |||
| Gastroesophageal junction | 10 (9.4) | 0 | 10 (12.7) | |
| Proximal | 19 (17.9) | 2 (7.4) | 17 (21.5) | |
| Body | 37 (34.9) | 12 (44.5) | 25 (31.7) | |
| Distal | 37 (34.9) | 12 (44.5) | 25 (31.7) | |
| Linitis | 3 (2.8) | 1 (3.6) | 2 (2.5) | |
Note: SD = standard deviation.
Unless indicated otherwise.
The same patient may have more than one value.
Patient operative characteristics
| Variable | No. (%) of patients | |||
|---|---|---|---|---|
| All | Pre-training | Post-training | ||
| T (pathological) | 0.70 | |||
| T1a | 10 (9.4) | 4 (14.8) | 6 (7.6) | |
| T1b | 14 (13.2) | 2 (7.4) | 12 (15.2) | |
| T2 | 11 (10.4) | 4 (14.8) | 7 (8.9) | |
| T3 | 44 (41.5) | 11 (40.7) | 33 (41.8) | |
| T4a | 21 (19.8) | 5 (18.5) | 16 (20.3) | |
| T4b | 6 (5.7) | 1 (3.7) | 5 (6.3) | |
| Sampled lymph nodes, median (range) | 29 (2–96) | 14 (2–92) | 33 (2–96) | < 0.0001 |
| Positive lymph nodes, median (range) | 2 (0–22) | 1 (0–22) | 2 (0–21) | 0.35 |
| Met the minimal requirement for lymph node dissection (≥ 16) | 82 (77.4) | 10 (37.0) | 72 (91.1) | < 0.0001 |
| N (pathological) | 0.39 | |||
| N0 | 39 (36.8) | 13 (48.2) | 26 (32.9) | |
| N1 | 25 (23.6) | 4 (14.8) | 20 (25.3) | |
| N2 | 22 (20.8) | 6 (22.2) | 17 (21.5) | |
| N3a | 15 (14.2) | 2 (7.4) | 13 (16.5) | |
| N3b | 5 (4.7) | 2 (7.4) | 3 (3.8) | |
| Node-positive cases | 67 (63.2) | 14 (51.9) | 53 (67.1) | 0.17 |
| M (pathological) | 0.99 | |||
| M0 | 99 (93.4) | 25 (92.6) | 74 (93.7) | |
| M1 | 7 (6.6) | 2 (7.4) | 5 (6.3) | |
| Grade | 0.09 | |||
| 1 | 15 (14.2) | 3 (11.1) | 12 (15.2) | |
| 2 | 37 (34.9) | 14 (51.9) | 23 (29.1) | |
| 3 | 54 (50.9) | 10 (37.0) | 44 (55.7) | |
| Positive for HER2 | 9 (8.5) | 1 (3.7) | 8 (10.1) | 0.44 |
| Diagnostic laparoscopy | 43 (40.6) | 12 (44.4) | 31 (39.2) | 0.66 |
| Surgery | 0.04 | |||
| Open | 67 (63.2) | 12 (44.4) | 55 (69.6) | |
| Laparoscopic | 39 (36.8) | 15 (55.6) | 24 (30.4) | |
| Conversion | 1 (0.9) | 1 (3.7) | 0 | |
| Gastrectomy | 0.12 | |||
| Total | 50 (47.2) | 9 (33.3) | 41 (51.9) | |
| Subtotal | 56 (52.8) | 18 (66.7) | 38 (48.1) | |
| Splenectomy | 26 (24.5) | 0 | 26 (32.9) | 0.0002 |
| Colectomy | 1 (0.9) | 0 | 1 (1.3) | 0.99 |
| Pancreatectomy | 8 (7.6) | 1 (3.7) | 7 (8.9) | 0.68 |
| Roux-en-Y reconstruction | 87 (82.1) | 13 (48.2) | 74 (93.7) | < 0.0001 |
| Gastric anastomosis | 0.08 | |||
| Sutured | 8 (7.6) | 4 (14.8) | 4 (5.1) | |
| Stapled | 85 (80.2) | 15 (55.6) | 70 (88.6) | |
| Intracorporeal | 1 (0.9) | 0 | 1 (1.3) | |
| Jejuno-jejunal anastomosis | < 0.0001 | |||
| Sutured | 9 (8.5) | 3 (11.1) | 6 (7.6) | |
| Stapled | 72 (67.9) | 10 (37.0) | 62 (78.5) | |
| Intracorporeal | 0 | 0 | 0 | |
| Feeding tube jejunostomy | 23 (21.7) | 16 (59.3) | 7 (8.9) | |
| Surgical margins, positive | 4 (3.8) | 0 | 4 (5.1) | 0.57 |
| Operating time, mean ± SD, min | 269 ± 71 | 284 ± 68 | 264 ± 71 | 0.24 |
| Blood loss, mean ± SD, mL | 367 ± 277 | 305 ± 307 | 385 ± 264 | 0.22 |
| Cases with complications | 25 (23.6) | 13 (48.2) | 12 (15.2) | 0.002 |
| Proximal leak | 1 (0.9) | 0 | 1 (1.3) | |
| Jejuno-jejunal leak | 1 (0.9) | 0 | 1 (1.3) | |
| Infection | 4 (3.8) | 2 (7.4) | 2 (2.5) | |
| Pneumonia | 8 (7.6) | 2 (7.4) | 6 (7.6) | |
| Acute coronary syndrome | 5 (4.7) | 3 (11.1) | 2 (2.5) | |
| Urinary infection | 1 (0.9) | 1 (3.7) | 0 | |
| Thrombosis | 3 (2.8) | 1 (3.7) | 2 (2.5) | |
| Incisional hernia | 2 (1.9) | 1 (3.7) | 1 (1.3) | |
| 30-day mortality | 3 (2.8) | 2 (7.4) | 1 (1.3) | |
| Reoperation for complication | 1 (0.9) | 1 (3.7) | 0 | |
| Length of stay, mean ± SD, d | 16 ± 26 | 23 ± 45 | 11 ± 7 | 0.03 |
| Neoadjuvant chemotherapy | 43 (40.6) | 10 (37.0) | 33 (41.8) | 0.82 |
| ECF | 25 (23.6) | 8 (29.6) | 17 (21.5) | |
| EOF | 1 (0.9) | 0 | 1 (1.3) | |
| EOX | 3 (2.8) | 1 (3.7) | 2 (2.5) | |
| DCF | 7 (6.6) | 0 | 7 (8.9) | |
| D-FOX | 6 (5.7) | 0 | 6 (7.6) | |
| Adjuvant radiotherapy | 8 (7.6) | 5 (18.5) | 3 (3.8) | 0.02 |
| Adjuvant chemotherapy | 30 (28.3) | 7 (25.9) | 23 (29.1) | 0.81 |
Note: DCF = Docetaxel, Cisplatin, 5-Fluorouracil; D-FOX = Docetaxel, Oxaliplatin, 5-Fluorouracil; ECF = Epiruicin, Cisplatin, 5-Fluorouracil; EOF = Epirubicin, Oxaliplatin, 5-Fluorouracil; EOX = Epirubicin, Oxaliplatin, Capecitabine; HER2 = human epidermal growth factor receptor 2 protein; M = metastasis; N = lymph node involvement; SD = standard deviation; T = tumour site.
Unless indicated otherwise.
The same patient may have more than one value.
Patient survival
| Variable | No. (%) of patients | |||
|---|---|---|---|---|
| All | Pre-training | Post-training | ||
| Follow-up, median (range), mo | 26 (1–142) | 39 (2–142) | 25 (1–74) | 0.0001 |
| Median survival (mo) | 39 | 29 | 47 | 0.026 |
| 12-month survival | 89 (83.9) | 20 (74.1) | 69 (87.3) | |
| 36-month survival | 58 (54.7) | 15 (55.6) | 58 (73.4) | |
| 60-month survival | 36 (33.9) | 5 (18.5) | 38 (48.1) | |
Unless indicated otherwise.
When considering equal follow-up between the 2 groups (i.e., censored at the longest follow-up in the post-training group) using log-rank test.
Fig. 1Overall survival of patients with gastric cancer before and after training in Japan (in months).